Cargando…
Accumulation of oncometabolite D-2-Hydroxyglutarate by SLC25A1 inhibition: A metabolic strategy for induction of HR-ness and radiosensitivity
Oncogenic mutations in metabolic genes and associated oncometabolite accumulation support cancer progression but can also restrict cellular functions needed to cope with DNA damage. For example, gain-of-function mutations in isocitrate dehydrogenase (IDH) and the resulting accumulation of the oncome...
Autores principales: | Xiang, Kexu, Kalthoff, Christian, Münch, Corinna, Jendrossek, Verena, Matschke, Johann |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307853/ https://www.ncbi.nlm.nih.gov/pubmed/35869047 http://dx.doi.org/10.1038/s41419-022-05098-9 |
Ejemplares similares
-
Oncometabolites and the response to radiotherapy
por: Xiang, Kexu, et al.
Publicado: (2020) -
Human Phosphoglycerate Dehydrogenase
Produces the
Oncometabolite d-2-Hydroxyglutarate
por: Fan, Jing, et al.
Publicado: (2014) -
The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway
por: Carbonneau, Mélissa, et al.
Publicado: (2016) -
The Enzymology of 2-Hydroxyglutarate, 2-Hydroxyglutaramate and 2-Hydroxysuccinamate and Their Relationship to Oncometabolites
por: Hariharan, Vivek A., et al.
Publicado: (2017) -
The Mitochondrial Citrate Carrier (SLC25A1) Sustains Redox Homeostasis and Mitochondrial Metabolism Supporting Radioresistance of Cancer Cells With Tolerance to Cycling Severe Hypoxia
por: Hlouschek, Julian, et al.
Publicado: (2018)